CytomX Current Deferred Revenue from 2010 to 2024
| CTMX Stock | USD 1.06 0.04 3.92% |
Current Deferred Revenue | First Reported 2014-12-31 | Previous Quarter 123.8 M | Current Value 96.1 M | Quarterly Volatility 37.9 M |
Check CytomX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytomX Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.1 M or Selling General Administrative of 28.8 M, as well as many indicators such as Price To Sales Ratio of 1.07, Dividend Yield of 0.0299 or Days Sales Outstanding of 11.76. CytomX financial statements analysis is a perfect complement when working with CytomX Therapeutics Valuation or Volatility modules.
CytomX | Current Deferred Revenue |
Latest CytomX Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of CytomX Therapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. CytomX Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytomX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
CytomX Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 47,815,557 | |
| Geometric Mean | 15,179,319 | |
| Coefficient Of Variation | 104.79 | |
| Mean Deviation | 40,790,727 | |
| Median | 40,559,000 | |
| Standard Deviation | 50,108,075 | |
| Sample Variance | 2510.8T | |
| Range | 138M | |
| R-Value | 0.94 | |
| Mean Square Error | 297.9T | |
| R-Squared | 0.89 | |
| Slope | 10,569,209 | |
| Total Sum of Squares | 35151.5T |
CytomX Current Deferred Revenue History
About CytomX Therapeutics Financial Statements
CytomX Therapeutics investors use historical fundamental indicators, such as CytomX Therapeutics' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CytomX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 132.3 M | 138.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.